Literature DB >> 22634429

MAGE-A antigens as targets in tumour therapy.

David W Meek1, Lynnette Marcar.   

Abstract

MAGE-A proteins constitute a sub-family of Cancer-Testis Antigens which are expressed mainly, but not exclusively, in germ cells. They are also expressed in various human cancers where they are associated with, and may drive, malignancy. MAGE-A proteins are highly immunogenic and are considered as potential targets for cancer vaccines and/or immuno-therapy. Moreover, recent advances in our understanding of their molecular pathology have revealed interactions that offer potential as therapeutic targets. Here we review recent progress in this area and consider how these interactions might be exploited, especially for the treatment of malignant cancers for which available treatments are inadequate.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22634429     DOI: 10.1016/j.canlet.2012.05.011

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  40 in total

1.  Overexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy target.

Authors:  Qing-Mei Zhang; Shu-Jia He; Ning Shen; Bin Luo; Rong Fan; Jun Fu; Guo-Rong Luo; Su-Fang Zhou; Shao-Wen Xiao; Xiao-Xun Xie
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 2.  Epigenetic alterations in osteosarcoma: promising targets.

Authors:  Binghao Li; Zhaoming Ye
Journal:  Mol Biol Rep       Date:  2014-02-06       Impact factor: 2.316

3.  Expression and prognostic value of MAGE-A9 in laryngeal squamous cell carcinoma.

Authors:  Liang Han; Bin Jiang; Hao Wu; Shu Zhang; Xueguan Lu
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

4.  DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11.

Authors:  Smitha R James; Carlos D Cedeno; Ashok Sharma; Wa Zhang; James L Mohler; Kunle Odunsi; Elizabeth M Wilson; Adam R Karpf
Journal:  Epigenetics       Date:  2013-07-09       Impact factor: 4.528

5.  MAGE-A1-6   expression in patients with head and neck squamous cell carcinoma: impact on clinical patterns and oncologic outcomes.

Authors:  Sang Tae Noh; Hyoung Shin Lee; Soo Jin Lim; Sung Won Kim; Hee Kyung Chang; Junghwan Oh; Chang-Ho Jeon; Jong Wook Park; Kang Dae Lee
Journal:  Int J Clin Oncol       Date:  2016-05-26       Impact factor: 3.402

Review 6.  Future directions in cancer prevention.

Authors:  Asad Umar; Barbara K Dunn; Peter Greenwald
Journal:  Nat Rev Cancer       Date:  2012-11-15       Impact factor: 60.716

7.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

8.  Antitumor effect of recombinant Mycobacterium smegmatis expressing MAGEA3 and SSX2 fusion proteins.

Authors:  Wen Jian; Xin Li; Jian Kang; Yingfeng Lei; Yinlan Bai; Ying Xue
Journal:  Exp Ther Med       Date:  2018-07-09       Impact factor: 2.447

9.  Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.

Authors:  David Escors
Journal:  New J Sci       Date:  2014-01-05

10.  Targeted drug delivery using an aptamer against shared tumor-specific peptide antigen of MAGE-A3.

Authors:  Chin-Yu Wang; Bai-Ling Lin; Chung-Hsuan Chen
Journal:  Cancer Biol Ther       Date:  2020-11-29       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.